Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NEK2 | P51955 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570524 | 0.88 | GPR119 (0.54) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL20571306 | 0.86 | HRH1 (0.44) | EPHX2HRH3 | |
| SCHEMBL22265776 | 0.83 | GPR119 (0.66) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL31071590 | 0.82 | GPR119 (0.57) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL8088637 | 0.82 | GPR119 (0.57) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL30272601 | 0.82 | GPR119 (0.57) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL20570501 | 0.82 | GPR119 (0.57) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL29828594 | 0.81 | EPHX2 (0.50) | EPHX2HRH3PDE4DALDH1A1 | |
| SCHEMBL22462874 | 0.81 | GPR119 (0.56) | GPR119EPHX2NEK2HRH3CHEK2 | |
| SCHEMBL8088551 | 0.81 | EPHX2 (0.62) | GPR119EPHX2NEK2HRH3CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| EP-3634404-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| CN-110678177-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018217809-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | GPR119 2756/4885EPHX2 2642/4885NEK2 1516/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | GPR119 2756/4885EPHX2 2642/4885NEK2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.